ArticleOncoimmunology2022
Article in Oncoimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 27 citations in OpenAlex.
- Microbiota as a modulator of drug response: targeting microbial-drug crosstalk in cancer therapy.Gut microbes · 2026Review
- Beyond PD-L1/PD-1: expression of PVR/TIGIT and TNFRSF14/BTLA axes in response to Helicobacter pylori and in gastric cancer lesions.ImmunoHorizons · 2026Article
- Analysis of intratumoural bacteria: Opportunities and challenges for cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Genetic insights into the relationship between anti-inflammatory drug target genes and oral diseases.Inflammopharmacology · 2025Article
- Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors.NPJ biofilms and microbiomes · 2025Article
- Review
- Relationship betweenWorld journal of clinical oncology · 2025Article
- The Skin Microbiome: A New Key Player in Melanoma, From Onset to Metastatic Stage.Pigment cell & melanoma research · 2025Review
- Lung cancer and the Gut-microbiota-lung Axis: emerging evidence and potential clinical implications.Frontiers in medicine · 2025Review
- Inhibition of the NF-κB/HIF-1α signaling pathway in colorectal cancer by tyrosol: a gut microbiota-derived metabolite.Journal for immunotherapy of cancer · 2024Article
- Unveiling the gastric microbiota: implications for gastric carcinogenesis, immune responses, and clinical prospects.Journal of experimental & clinical cancer research : CR · 2024Review
- Intratumoural microbiota: a new frontier in cancer development and therapy.Signal transduction and targeted therapy · 2024Review
- Melanoma and microbiota: Current understanding and future directions.Cancer cell · 2024Review
- Effects and mechanisms ofFrontiers in immunology · 2024Review
- Article
- Cross-talk betweenFrontiers in cellular and infection microbiology · 2024Article
- Immune-reactive tumor organoids system to determine the effects of microbial metabolites on cancer immunity and immunotherapies.Frontiers in microbiomes · 2024Article
- Review
- [CanThe Korean journal of helicobacter and upper gastrointestinal research · 2023Article
- Impact ofJournal for immunotherapy of cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
26 authors at 7 institutions in 5 countries.
Funding
Abstract
The microbiome is now regarded as one of the hallmarks of cancer and several strategies to modify the gut microbiota to improve immune checkpoint inhibitor (ICI) activity are being evaluated in clinical trials. Preliminary data regarding the upper gastro-intestinal microbiota indicated that
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.